Physician profile
Eva Catalan
NPI 1174125272
$9,637.80
in general payments reported to CMS, 2019-2025
57 companies · $4,600 in 2025
The $4,600 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.76 · 2022: $145 · 2023: $399 · 2024: $4,482 · 2025: $4,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,382 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,381.81 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $402.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,224.73 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $749.63 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $510.22 | 2024-2025 | Tecvayli, Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $479.20 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Pfizer INC. | $427.73 | 2024-2025 | |
| Astellas Pharma US INC | $324.98 | 2024-2025 | Xospata, Vyloy, Padcev |
| Incyte Corporation | $324.29 | 2024-2025 | Jakafi, Monjuvi |
| Tempus Ai, INC | $292.23 | 2024-2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $287.13 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Merck Sharp & Dohme LLC | $275.06 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $268.41 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.42 | 2024-2025 | |
| Gilead Sciences, INC. | $251.05 | 2023-2025 | Trodelvy |
| Eisai INC. | $216.82 | 2023-2025 | |
| Genzyme Corporation | $205.46 | 2023-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $159.66 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.97 | 2024-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $139.02 | 2024-2025 | Libtayo, Lynozyfic |
| Celgene Corporation | $134.65 | 2024-2025 | Reblozyl, Pomalyst |
| Array Biopharma INC | $126.83 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $121.77 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Springworks Therapeutics, INC. | $103.60 | 2024-2025 | Ogsiveo, Gomekli |
| Servier Pharmaceuticals LLC | $97.94 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $95.40 | 2025 | Myrisk |
| Kite Pharma, INC. | $90.54 | 2024-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $86.82 | 2023-2024 | Xpovio |
| Lilly USA, LLC | $81.74 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Seagen INC. | $78.75 | 2025 | |
| Dendreon Pharmaceuticals LLC | $76.95 | 2024-2025 | Provenge |
| Stemline Therapeutics INC. | $71.91 | 2024-2025 | Orserdu |
| Blueprint Medicines Corporation | $68.55 | 2024-2025 | Ayvakit |
| Taiho Oncology, INC. | $67.56 | 2024-2025 | |
| Emd Serono, INC. | $63.62 | 2023-2024 | Bavencio |
| Rigel Pharmaceuticals, INC. | $62.10 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Jazz Pharmaceuticals INC. | $60.01 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.69 | 2024-2025 | Gilotrif |
| Tersera Therapeutics LLC | $57.40 | 2023-2025 | Zoladex |
| Shield Therapeutics INC | $55.14 | 2024-2025 | |
| Caris Mpi, INC. | $43.38 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $36.04 | 2023-2024 | Monjuvi |
| Genentech USA, INC. | $35.91 | 2024 | Tecentriq, Polivy |
| Alexion Pharmaceuticals, INC. | $35.89 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $33.46 | 2024 | Pyrukynd |
| Puma Biotechnology, INC. | $27.36 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $27.33 | 2024 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $24.03 | 2024 | Qinlock |
| Geron Corporation | $22.95 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $19.08 | 2024 | |
| Recordati_rare_diseases_inc. | $17.98 | 2024 | Sylvant |
| Tactile Systems Technology INC | $17.62 | 2022 | |
| Novo Nordisk INC | $16.76 | 2024 | Esperoct |
| Immunocore Limited | $16.56 | 2024 | Kimmtrak |
| Acrotech Biopharma INC. | $15.38 | 2024 | Beleodaq |
| Genmab U.S., INC. | $14.99 | 2024 | Epkinly |
| Ultragenyx Pharmaceutical INC. | $14.62 | 2022 | |
| Medtronic, INC. | $13.84 | 2022 | |
| Iovance Biotherapeutics, INC. | $10.64 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Catalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.